An exploratory study of venetoclax in combination with bortezomib-cyclophosphamide-dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies.

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)
  • Mollee, Peter N. (Chief Investigator (CI))
  • Harrison, Simon James (Chief Investigator (CI))
  • Quach, Hang (Chief Investigator (CI))
  • Ho, Phoebe Joy (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date27/09/18 → 27/09/23

Clinical Trial Phase

  • Phase II